Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.
MERS-CoV
MVA
antibody
camel
mice
vaccine
viral vector
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
17 Aug 2022
17 Aug 2022
Historique:
received:
14
06
2022
revised:
12
08
2022
accepted:
15
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen that can transmit from dromedary camels to humans, causing severe pneumonia, with a 35% mortality rate. Vaccine candidates have been developed and tested in mice, camels, and humans. Previously, we developed a vaccine based on the modified vaccinia virus Ankara (MVA) viral vector, encoding a full-length spike protein of MERS-CoV, MVA-MERS. Here, we report the immunogenicity of high-dose MVA-MERS in prime-boost vaccinations in mice and camels. Three groups of mice were immunised with MVA wild-type (MVA-wt) and MVA-MERS (MVA-wt/MVA-MERS), MVA-MERS/MVA-wt, or MVA-MERS/MVA-MERS. Camels were immunised with two doses of PBS, MVA-wt, or MVA-MERS. Antibody (Ab) responses were evaluated using ELISA and MERS pseudovirus neutralisation assays. Two high doses of MVA-MERS induced strong Ab responses in both mice and camels, including neutralising antibodies. Anti-MVA Ab responses did not affect the immune responses to the vaccine antigen (MERS-CoV spike). MVA-MERS vaccine, administered in a homologous prime-boost regimen, induced high levels of neutralising anti-MERS-CoV antibodies in mice and camels. This could be considered for further development and evaluation as a dromedary vaccine to reduce MERS-CoV transmission to humans.
Identifiants
pubmed: 36016218
pii: vaccines10081330
doi: 10.3390/vaccines10081330
pmc: PMC9413082
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : King Abdulaziz City for Science and Technology
ID : 1-34
Références
Curr Opin Biotechnol. 2004 Dec;15(6):506-12
pubmed: 15560976
J Clin Invest. 2008 May;118(5):1776-84
pubmed: 18398511
J Virol. 2016 Dec 16;91(1):
pubmed: 27795425
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Emerg Infect Dis. 2021 May;27(5):
pubmed: 33900908
Emerg Infect Dis. 2015 Jun;21(6):1019-22
pubmed: 25989145
J Virol. 2009 Mar;83(6):2540-52
pubmed: 19129447
Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90
pubmed: 219640
Vaccine. 2013 Sep 6;31(39):4241-6
pubmed: 23523410
Infect Ecol Epidemiol. 2015 Jul 15;5:28305
pubmed: 26183160
Lancet Infect Dis. 2020 Jul;20(7):816-826
pubmed: 32325038
Hum Gene Ther. 2014 Apr;25(4):285-300
pubmed: 24499174
Lancet Infect Dis. 2013 Oct;13(10):859-66
pubmed: 23933067
J Infect Dis. 2019 Oct 8;220(10):1558-1567
pubmed: 30911758
Vaccine. 2011 Jul 26;29(33):5331-9
pubmed: 21664218
Expert Rev Vaccines. 2009 Jun;8(6):761-77
pubmed: 19485756
J Virol. 2017 Jan 3;91(2):
pubmed: 27807241
Nat Med. 2008 Aug;14(8):819-21
pubmed: 18660818
J Mol Biol. 1989 Dec 20;210(4):749-69
pubmed: 2515286
Vaccine. 2010 Feb 3;28(5):1209-16
pubmed: 19944151
Vaccine. 2017 Jun 27;35(30):3780-3788
pubmed: 28579232
One Health. 2017 Mar 10;3:41-43
pubmed: 28616502
Viruses. 2019 Mar 02;11(3):
pubmed: 30832356
PLoS One. 2013 Aug 12;8(8):e73511
pubmed: 23951355
Sci Rep. 2019 Nov 8;9(1):16292
pubmed: 31705137
PLoS Pathog. 2009 Jun;5(6):e1000480
pubmed: 19543380
Lancet Microbe. 2022 Jan;3(1):e11-e20
pubmed: 34751259
Lancet Planet Health. 2019 Dec;3(12):e521-e528
pubmed: 31843456
Biotechniques. 1997 Dec;23(6):1094-7
pubmed: 9421642
J Infect Public Health. 2018 May - Jun;11(3):331-338
pubmed: 28993171
J Virol. 2015 Aug;89(16):8651-6
pubmed: 26018172
Nucleic Acids Res. 1990 Jul 25;18(14):4285-6
pubmed: 2377486
J Integr Agric. 2017 Oct;16(10):2264-2273
pubmed: 32288953
Euro Surveill. 2013 Dec 12;18(50):20662
pubmed: 24342516
MethodsX. 2015 Oct 13;2:379-84
pubmed: 26587388
NPJ Vaccines. 2017 Oct 16;2:28
pubmed: 29263883
Vaccine. 2014 May 30;32(26):3169-3174
pubmed: 24736006
Vaccine. 2016 Jan 2;34(1):49-55
pubmed: 26616553
PLoS One. 2015 Jun 08;10(6):e0128626
pubmed: 26053118
Emerg Infect Dis. 2017 Mar;23(3):550-551
pubmed: 28221127
PLoS One. 2020 May 26;15(5):e0232790
pubmed: 32453746
Lancet Infect Dis. 2020 Jul;20(7):827-838
pubmed: 32325037
Z Immunitatsforsch Exp Klin Immunol. 1972 Sep;144(2):104-56
pubmed: 4282933
Vaccine. 2014 Oct 21;32(46):6170-6176
pubmed: 25240756
J Virol Methods. 1997 Jun;66(1):135-8
pubmed: 9220399
Methods Mol Biol. 2020;2099:117-126
pubmed: 31883092
Pathog Glob Health. 2015;109(8):354-62
pubmed: 26924345
Viruses. 2020 Oct 27;12(11):
pubmed: 33120981
Lancet Infect Dis. 2019 Sep;19(9):1013-1022
pubmed: 31351922
Vaccine. 2013 Sep 6;31(39):4235-40
pubmed: 23523402
Sci Transl Med. 2015 Aug 19;7(301):301ra132
pubmed: 26290414
PLoS One. 2012;7(6):e40167
pubmed: 22761956
Clin Infect Dis. 2022 Jun 08;:
pubmed: 35675306
Emerg Infect Dis. 2014 Dec;20(12):2093-5
pubmed: 25425139
Science. 2016 Jan 1;351(6268):77-81
pubmed: 26678878
PLoS One. 2008 Feb 20;3(2):e1638
pubmed: 18286194
J Virol. 1993 Sep;67(9):5394-401
pubmed: 8350402
Vaccine. 2010 Feb 10;28(6):1547-57
pubmed: 19969118
Hum Vaccin Immunother. 2019;15(1):203-209
pubmed: 30148692
Expert Rev Vaccines. 2011 Oct;10(10):1435-49
pubmed: 21988308
Sci Rep. 2017 Mar 23;7:44875
pubmed: 28332568